cervic
cancer
mainli
associ
hpv
genotyp
infect
recombin
measl
viru
rmv
express
hpv
genotyp
capsid
protein
gener
construct
antigenom
plasmid
follow
rescu
use
human
helper
cell
line
cell
cultur
recombin
viru
replic
practic
effici
standard
attenu
mv
establish
commerci
vaccin
devoid
transgen
high
genet
stabil
confirm
serial
viral
transfer
cell
cultur
transgen
mice
express
mv
receptor
recombin
induc
strong
humor
immun
respons
mv
hpv
antibodi
exhibit
mainli
neutral
capac
data
suggest
mv
promis
vehicl
develop
inexpens
effici
vaccin
protect
hpv
infect
human
papilloma
virus
hpv
belong
larg
famili
small
doublestrand
dna
virus
infect
squamou
epitheli
cell
date
genotyp
describ
among
least
type
infect
genit
tract
although
hpv
produc
benign
lesion
small
subset
strongli
associ
develop
highgrad
squamou
intraepitheli
lesion
cervic
cancer
subset
identifi
high
risk
estim
account
approxim
cervic
cancer
ad
anoth
everi
year
approxim
half
million
new
cervic
cancer
case
regist
worldwid
particularli
develop
countri
repres
second
common
caus
mortal
women
hpv
dna
found
cancer
pap
smear
screen
identifi
premalign
lesion
molecular
diagnos
avail
identifi
hpv
infect
appropri
treatment
prevent
case
develop
cervic
cancer
howev
hpv
test
limit
social
issu
high
cost
thu
develop
vaccin
prevent
hpv
infect
repres
import
opportun
prevent
cervic
cancer
whilst
therapeut
immun
would
valuabl
treat
premalign
malign
diseas
hpv
genom
encod
eight
protein
late
gene
code
capsid
protein
earli
gene
respons
viral
replic
transcript
present
cervic
carcinoma
cell
induc
hpv
structur
protein
high
risk
type
repres
optim
target
prophylact
vaccin
actual
sever
prophylact
hpv
vaccin
formul
base
upon
major
viral
capsid
protein
either
monom
viru
like
particl
vlp
bival
cervatrix
gsk
contain
hpv
quadrival
gardasil
merck
contain
addit
deriv
hpv
vaccin
highli
immunogen
appear
safe
although
advers
effect
describ
nevertheless
high
cost
permit
gener
access
popul
risk
particularli
relev
develop
countri
thu
recombin
measl
viru
rmv
express
insert
transgen
might
constitut
suitabl
second
gener
vaccin
mv
belong
famili
paramyxovirid
genu
morbilliviru
envelop
viru
nonseg
tightli
encapsid
negativestrand
rna
genom
attenu
mv
strain
highli
effici
safe
vaccin
typic
protect
recipi
measl
entir
life
benefit
extraordinari
vaccin
properti
mv
cdna
plasmid
construct
produc
precis
initi
termin
mv
antigenom
relat
edmonston
b
vaccin
strain
helpercellbas
system
establish
allow
rescu
mv
mv
antigenom
plasmid
technolog
allow
construct
genet
alter
mv
recombin
mv
deriv
rmv
express
protein
insert
transgen
complex
rmv
gener
far
exceed
length
standard
mv
nucleotid
contain
code
region
green
fluoresc
protein
gfp
betagalactosidas
chloramphenicol
acetyl
transferas
cat
engin
three
posit
mv
antigenom
insert
code
region
express
independ
transcript
unit
transgen
express
differ
level
accord
genom
posit
stabli
maintain
mani
viral
gener
abil
construct
new
recombin
chimer
mv
open
prospect
develop
new
vaccin
base
mv
limit
immun
experi
carri
far
rmv
encourag
effort
gener
inexpens
candid
hpv
vaccin
improv
prophylact
potenti
mv
vector
base
bernacommerci
vaccin
strain
moraten
berna
measl
viru
induc
immun
hpv
develop
sequenc
encod
hpv
insert
mv
genom
recombin
viru
obtain
use
system
rescu
mv
viru
express
protein
high
level
induc
humor
immun
respons
mv
genet
modifi
mice
cell
maintain
monolay
dulbecco
modifi
eagl
medium
supplement
fetal
calf
serum
fc
vero
african
green
monkey
kidney
cell
fc
mg
per
ml
stabli
transfect
cell
cell
cultur
berna
biotech
product
medium
supplement
fb
absenc
antibiot
cell
cultur
grown
co
plasmid
p
construct
base
p
vector
nomenclatur
p
mv
stand
plasmid
deliv
correctli
ribozymetermin
antigenom
mv
rna
b
specifi
berna
vaccin
strain
sequenc
number
indic
place
addit
transcript
unit
atu
insert
upstream
n
gene
p
gene
h
l
gene
posit
use
transgen
orf
append
directli
number
indic
posit
atu
hpv
gene
sourc
rhein
biotech
germani
amplifi
pcr
use
follow
oligo
gcgcgc
c
atg
agc
ctg
tgg
ctg
rev
gacgtc
tca
cag
ctt
cct
ctt
ctt
care
respect
bsshii
aatii
clone
site
underlin
boldfac
pcr
product
digest
bsshii
aatii
insert
p
zuniga
et
al
prepar
use
enzym
obtain
p
clone
procedur
perform
basic
describ
previous
sequenc
confirm
sequenc
entir
insert
region
plasmid
rescu
recombin
essenti
describ
previous
singl
syncytia
transfer
cell
cultur
well
sixwel
plate
transfer
cm
flask
cellfre
viru
harvest
accord
standard
sop
supernat
clarifi
cell
debri
kept
viru
titr
determin
plaqu
assay
vero
cell
briefli
serial
dilut
virus
inocul
onto
vero
cell
monolay
well
h
viru
adsorpt
inoculum
remov
cell
overlaid
ml
dulbecco
modifi
eagl
medium
contain
fc
low
melt
agaros
five
day
later
cultur
fix
ml
trichloroacet
acid
h
remov
agaros
overlay
monolay
stain
crystal
violet
rescu
recombin
virus
serial
propag
time
cell
multipl
infect
moi
stabil
protein
express
determin
passag
end
titer
determin
passag
viru
reproduct
analyz
infect
cell
monolay
well
moi
plate
incub
h
viru
adsorpt
inoculum
remov
cell
overlaid
ml
dulbecco
modifi
eagl
medium
contain
fc
plate
incub
infect
cell
collect
h
postinocul
hpi
centrifug
medium
resuspend
cell
lyse
freez
thaw
viru
titer
determin
plaqu
assay
monolay
vero
cell
grown
sixwel
plate
infect
moi
either
mvb
cell
harvest
hpi
process
sdspage
polyacrylamid
gel
electrophoresi
detect
mous
monoclon
antibodi
biogenesi
secondari
goat
antimous
antibodyhorseradish
peroxidas
hrpo
conjug
dako
glostrup
denmark
accord
enhanc
chemiluminesc
protocol
amersham
monolay
vero
cell
grown
tissu
cultur
chamber
slide
life
technolog
milano
itali
infect
either
mvb
moi
h
fix
paraformaldehyd
min
follow
permeabil
triton
sigma
block
min
pbsbsa
cell
consecut
process
mous
monoclon
antibodi
biogenesi
goat
antimous
antibodyfluorescein
isothiocyan
fitc
conjug
serotec
ltd
oxford
england
number
fluoresc
nonfluoresc
syncytia
count
use
leica
microscop
immunogen
activ
rescu
virus
evalu
mvsuscept
transgen
mice
anim
kept
optim
hygien
condit
immun
week
age
group
five
mice
immun
boost
intraperiton
ip
use
pfu
week
mice
immun
pb
serv
control
uvinactiv
mv
use
control
determin
effect
viru
replic
activ
immun
respons
sera
analyz
hpv
mv
antibodi
elisa
hpv
neutral
assay
presenc
mvspecif
antibodi
antibodi
sera
immun
ifnar
mice
determin
elisa
assay
briefli
plate
coat
measl
viru
eia
bulk
atcc
antigen
dilut
carbon
buffer
ph
concentr
ng
well
respect
plate
incub
overnight
wash
tween
pbst
subsequ
unspecif
interact
block
defat
milk
dissolv
pt
h
well
wash
pbst
serial
twofold
dilut
test
sera
ad
plate
incub
min
plate
wash
pbst
incub
ml
goat
antimouseigghrp
dilut
pbst
min
plate
wash
pbst
incub
ml
opd
ophenylendiamin
fluka
reaction
stop
min
plate
read
microelisa
tearder
wave
length
nm
od
valu
higher
threefold
valu
neg
control
score
posit
reaction
assay
neutral
antibodi
pfu
hpv
incub
twofold
serum
dilut
h
subsequ
vero
cell
inocul
duplic
plate
five
day
later
titer
determin
microscop
endpoint
titer
calcul
highest
serum
dilut
test
reduc
number
pfu
least
orf
encod
insert
p
vector
vector
p
modifi
accept
addit
transgen
posit
p
gene
insert
atu
form
independ
gene
p
gene
fig
technic
orf
amplifi
pcr
result
product
clone
mvb
genom
context
via
bsshii
aatii
fig
recombin
plasmid
p
use
rescu
recombin
virus
helper
cell
line
recombin
amplifi
cell
cultur
infect
suitabl
dilut
recombin
viru
stock
screen
express
immunofluoresc
syncytia
rescu
show
posit
signal
fig
wherea
syncytia
rescu
mvb
fig
show
fluoresc
indic
syncytia
induc
express
express
confirm
western
blot
fig
vero
cell
infect
mvb
either
medium
cell
lysat
analyz
antibodi
react
protein
approxim
kda
synthes
cell
present
also
medium
cultur
wherea
protein
neither
detect
mvbinfect
cell
lysat
medium
fig
protein
usual
form
vpl
capsomer
shown
other
think
express
mv
vector
also
allow
secret
induc
format
vlp
determin
whether
orf
encod
stabli
maintain
recombin
viru
serial
propag
time
vero
cell
moi
recombin
virus
passag
use
infect
vero
cell
cultur
coverslip
show
cytopath
effect
express
detect
immunofluoresc
syncytia
induc
passag
recombin
virus
test
show
posit
signal
wherea
syncytia
rescu
mvb
show
fluoresc
data
shown
thu
even
extens
amplif
appar
none
recombin
progeni
lost
capac
express
transgen
cell
plate
infect
mvb
moi
day
time
point
indic
cellfre
viru
cellassoci
viru
collect
separ
viru
titr
determin
plaqu
assay
replic
cellassoci
reach
peak
titer
pfuml
hpi
wherea
mvb
gave
final
titer
pfuml
hpi
fig
ca
replic
cellfre
reach
peak
titer
pfuml
hpi
almost
ident
cell
free
mvb
replic
fig
cf
humor
immun
respons
induc
rescu
virus
mvb
monitor
genet
modifi
mice
devoid
interferon
type
receptor
express
human
yac
result
humanlik
tissu
distribut
analysi
presenc
antibodi
sera
mice
immun
recombin
standard
mv
elisa
neutral
test
indic
mice
immun
mount
humor
respons
specif
igg
titer
neutral
titer
close
correspond
tabl
sera
also
probe
antimv
antibodi
antibodi
titer
induc
transgen
mice
least
equival
induc
standard
tripl
inject
cervatrix
human
immun
respons
direct
mv
ident
anim
immun
standard
recombin
viru
attempt
develop
inexpens
hpv
vaccin
candid
improv
prophylact
potenti
gener
recombin
mv
express
protein
orf
insert
p
gene
mv
genom
protein
stabli
express
even
serial
viru
passag
cell
shown
immunofluoresc
western
blot
analysi
replic
kinet
recombin
almost
indistinguish
parent
mvb
behaviour
appear
unusu
given
fact
mani
orf
insert
mv
vector
slow
propag
recombin
yet
other
slightli
cell
cultur
propag
properti
appear
particularli
favour
case
vaccin
candid
consid
fact
gener
insert
addit
gene
genom
virus
belong
mononegaviral
shown
result
slower
viral
growth
kinet
due
alter
gene
express
gradient
review
recombin
mononegaviral
particular
rmv
see
rescu
seem
faith
maintain
insert
code
sequenc
multipl
passag
cell
cultur
although
exclud
possibl
extens
amplif
factor
minor
mutat
aris
howev
stabil
express
extens
amplif
suggest
surprisingli
high
fidel
mv
rna
polymeras
essenti
rna
recombin
copi
choic
would
eventu
lead
delet
well
known
literatur
assembl
vlp
gener
vlp
format
associ
strong
immunogen
potenti
protein
secret
medium
infect
cell
appear
like
assembl
viral
pentamer
capsomer
form
vpl
howev
work
need
prove
phenomenon
explor
potenti
vaccin
humor
immun
respons
protein
monitor
immun
genet
modifi
mice
mice
express
human
first
character
mv
receptor
humanlik
tissu
specif
mice
inocul
produc
high
antibodi
titer
elisa
neutral
assay
similar
observ
women
mice
three
im
inject
vlp
similar
titer
two
assay
indic
specif
igg
gener
mainli
neutral
antibodi
although
actual
prophylact
hpv
vaccin
effect
prevent
infect
target
strain
human
papillomaviru
appear
safe
high
cost
limit
mass
hpv
immun
program
particularli
develop
countri
benefit
fulli
assess
particular
given
fact
one
applic
standard
mv
vaccin
typic
protect
recipi
entir
life
may
well
protect
hpv
exert
mvhpv
recombin
may
longer
durat
mvbase
vector
system
sever
advantag
comparison
viral
vector
system
deliveri
foreign
protein
immun
purpos
first
use
mv
strain
alreadi
use
safe
efficaci
vaccin
product
cost
mv
vaccin
low
current
mv
vaccin
well
known
induc
solid
lifelong
immun
prefer
applic
benefici
particularli
develop
countri
use
mv
vector
cocktail
deliv
simultan
sever
addit
antigen
could
envisag
instead
routin
mv
vaccin
earli
childhood
final
plastic
mv
abil
stabli
express
foreign
gene
even
multipl
passag
suggest
far
better
deliveri
system
rna
viru
vector
unabl
accommod
larg
foreign
sequenc
icosahedr
capsid
often
rapidli
lose
even
small
insert
due
depend
suitabl
rna
secondari
tertiari
structur
well
high
level
recombin
characterist
render
recombin
attract
candid
develop
prophylact
low
cost
vaccin
hpv
infect
eventu
addit
insert
earli
hpv
gene
appear
perfectli
feasibl
might
allow
recombin
also
therapeut
use
treat
individu
persist
infect
hpv
even
alreadi
affect
cervic
carcinoma
construct
recombin
p
plasmid
gene
amplifi
pcr
result
product
clone
mv
genom
context
via
bsshii
aatii
immunofluoresc
analysi
express
protein
recombin
mv
monolay
vero
cell
grown
tissu
cultur
chamber
slide
infect
either
mvb
either
b
moi
h
process
immunofluoresc
cell
stain
monoclon
antibodi
subsequ
goat
antimous
coupl
fitc
green
slide
stain
dapi
visual
invert
leica
microscop
normal
fluoresc
light
respect
interpret
refer
color
figur
legend
reader
refer
web
version
articl
growth
curv
comparison
mvb
cell
sixwel
plate
infect
mvb
moi
day
time
point
indic
media
cellfre
cf
viru
cell
cellassoci
ca
viru
collect
separ
viru
titer
determin
plaqu
assay
